Healthcare

• Acadia's net sales were US$125 million, up from US$101 million in the first quarter of 2026, according to Neuren's August announcements.

• Net Ryoncil product sales were US$115.2 million, after a 13.4 per cent gross-to-net adjustment, compared with US$11.3 million in the prior year.

• About US$1.25 billion of that is to be paid in Telix shares, issued to ITM holders as American depositary receipts.

• GroupRevenuerose 5.9% to A$9,115.2 million, group operating profit rose 6.7% to A$813.5 million, and underlying net profit after tax (NPAT) rose 2.9% to A$636.8 million.

• The company says it received FDA clearance in September 2025, and that US reimbursement of US$650.50 per scan was confirmed shortly afterwards.

• Sales were a record US$2,140.2 million, up 6.8 per cent, with organic constant-currency growth of 5.0 per cent.

• Second-half constant currency growth was 6%, which management presented as evidence of improving momentum.